6f0bb404-250a-4f9c-ac7b-c2468626c875

The investment community is keeping a watchful eye on Biotech Portage Biotech Inc. (OTC Market: PTGEF; Canadian Securities Exchange: PBT.U).

Portage is still relatively unknown, as management has been quietly focusing on building the company and acquiring stock. They have not yet actively pursued an Investors Relations campaign, but are looking into one very soon. This could be the right time to look into Portage as an investment opportunity! Portage Biotech is poised to turn the Biotech industry on its head.

The 3 largest shareholders are Portage’s Chairman Dr. Gregory Bailey M.D., CEO, Dr. Declan Doogan M.D., and Director, renowned investor Jim Mellon. Together they own over 50% of the stock. Equally important, is they are buyers! Bailey and Mellon subscribed to a total of $2.6 million into the last 2 private placements. They have also been buying large blocks on the open market. From March 2015 to present total purchases in excess of 18 million shares between them. This reflects the confidence that executives and management have in the company.

PTGEF may look like a start up on the surface; however under the hood, the engine is powered by some of the most well-known names in the business. At the helm is former Pfizer superstar Declan Doogan MD, their CEO who most notably played a key role in the development of one of today’s most well-known drugs – Zoloft. He’s joined by a rock-star executive team who bring a combined 200+ years of pharmaceuticals experience to the firm from some of the most well-known banners in the world.

It took this exceptional team a mere 18 months to make the huge leap from being a preclinical stage Company to that of one clinically testing out its inaugural candidate to treat General Anxiety Disorder (and other CNS indications). Portage Biotech plans to move more candidates into the clinic this year.

Portage’s strategy is as simple as it is savvy: they’re engaged in researching and developing pharmaceutical and biotech products through to clinical “proof of concept” with an initial focus on unmet clinical needs. Following proof of concept, Portage looks to sell or license their products to large pharmaceutical companies for further development and commercialization.

Herein lays the brilliance of what PORTAGE BIOTECH IN COM NPV (OTCMKTS:PTGEF) brings to the table with their ultra-innovative ‘develop until proof of concept’ strategy. By tapping into some of the best minds in the game and funneling their resources into the Research and Development of their pipeline, and leaving the burden of hefty marketing and production costs to others, they can focus on what they do best – innovate and deliver life changing products!

Portage has a couple of explosive, life changing products poised to turn the industry on its head. They have some game-changing products in their pipeline that, if brought to market, will send shockwaves through the industry. Those in the industry know and the capital markets are highly anticipating and exuberant about the thought of them coming to fruition.

Considering the massive impact these products could have on the industry, it’s no wonder Biopharmaceutical enthusiast and popular investment guru Jim Mellon hitched his wagon to Portage by joining their board of directors – he knows a winner when he sees it! His optimistic view was on further display during his recent presentation at the Master Investor Show, where he included Portage Biotech Inc. on his list of long recommendations.

There’s something BIG happening over at Portage Biotech Inc. suggesting that more breakthrough ideas are still to come, and they want more skin in the game! !

Company website: www.portagebiotech.com

Subsidiary website: http://biohavenpharma.com/

Don’t Miss Next Alert. Subscribe Right Now!

PORTAGE BIOTECH IN COM NPV(OTCMKTS:PTGEF)

We will be updating on PTGEF when more details emerge so make sure you are subscribed to Microcapspot so you know what’s going on with PTGEF.

Disclosure: we hold no position in PTGEF either long or short at the publication of this article.

SHARE

NO COMMENTS

LEAVE A REPLY